Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 10/20 | 0.69 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.70 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.65 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | AGXT | P21549 | 1/20 | 0.48 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919783 | 0.98 | LOXL2 (0.73) | LOXL2MAOBST14IDO1AGXT | |
| SCHEMBL4209153 | 0.86 | ST14 (0.85) | LOXL2MAOBST14 | |
| Hydrochloric Acid SCHEMBL3830237 | 0.86 | LOXL2 (0.94) | LOXL2MAOBIDO1AGXTTAAR1 | |
| Hydrochloric Acid SCHEMBL3847812 | 0.86 | LOXL2 (0.94) | LOXL2MAOBIDO1AGXTTAAR1 | |
| Hydrochloric Acid SCHEMBL922110 | 0.85 | ST14 (0.53) | LOXL2MAOBST14 | |
| SCHEMBL21063 | 0.83 | — | — | |
| SCHEMBL506985 | 0.83 | ST14 (0.73) | LOXL2MAOBST14TAAR1 | |
| SCHEMBL184274 | 0.83 | ST14 (0.55) | LOXL2MAOBST14 | |
| Water SCHEMBL919765 | 0.81 | ST14 (0.53) | LOXL2MAOBST14 | |
| Bromide SCHEMBL31513710 | 0.81 | LOXL2 (0.94) | LOXL2MAOBIDO1AGXTTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875029-B1 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | MORASKI GARRETT (US) | 2021-11-10 | — | — | EP | disclosed |
| US-9605002-B2 | 5,5-heteroaromatic anti-infective compounds | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150210715-A1 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC | 2015-07-30 | — | — | US | disclosed |
| CN-104718213-A | 5, 5-heteroaromatic anti-infective compounds | UNIV NOTRE DAME | 2015-06-17 | — | — | CN | disclosed |
| EP-2875029-A2 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | Moraski, Garrett (US) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014015167-A2 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2009117421-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-1462439-B1 | NOVEL STABLE CRYSTALS OF SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | KYORIN SEIYAKU KK (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-7279596-B2 | Stable crystals of substituted phenylpropionic acid derivative and process for producing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-09 | — | — | US | disclosed |
| US-20050228050-A1 | Novel stable crystals of substituted phenylpropionic acid derivative and process for producing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| EP-1462439-A1 | NOVEL STABLE CRYSTALS OF SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-09-29 | — | — | EP | disclosed |
| JP-2003212833-A | PRODUCTION INTERMEDIATE | KYORIN PHARMACEUT CO LTD | 2003-07-30 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228050-A1 | Novel stable crystals of substituted phenylpropionic acid derivative and process for producing the same | ADH1A, ADH1C, ADH5 | MAOB 2802/4885LOXL2 4416/4885ST14 3527/4885 |
| US-20150210715-A1 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | API5, CASP5, IL5 | MAOB 2786/4885LOXL2 3767/4885ST14 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.